chrisvoncsefalvay/vaers-outcomes huggingface dataset:
the injection site was became very red & swollen with fine blisters that ran down her arm to her elbow; the injection site was became very red & swollen with fine blisters that ran down her arm to her elbow; the injection site was became very red & swollen with fine blisters that ran down her arm to her elbow; the injection site was became very red & swollen with fine blisters that ran down her arm to her elbow; Initial information received on 01-Nov-2019 regarding an unsolicited valid non-serious case received from a other health professional.  This case involves a 3 years (reported as 3 years and 5 month) old female patient who experienced the injection site was became very red & swollen with fine blisters that ran down her arm to her elbow (extensive swelling of vaccinated limb, erythema, vaccination site reaction and blister), while she received vaccine INFLUENZA QUADRIVAL A-B MULTIDOSE VACCINE PRESERVED [FLUZONE].  The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided.   On 15-Oct-2019, the patient received a 0.5 mL dose of suspect INFLUENZA QUADRIVAL A-B MULTIDOSE VACCINE PRESERVED lot UJ237AB, expiry date: 30-Jun-2020, via intramuscular route in the left arm.  On an unknown date, the patient developed a non-serious the injection site was became very red & swollen with fine blisters that ran down her arm to her elbow (extensive swelling of vaccinated limb, erythema, vaccination site reaction and blister), unknown latency following the administration of INFLUENZA QUADRIVAL A-B MULTIDOSE VACCINE PRESERVED.  Other relevant tests were not reported.  Final diagnosis was the injection site was became very red & swollen with fine blisters that ran down her arm to her elbow.  The patient was treated with DIPHENHYDRAMINE HYDROCHLORIDE (BENADRYL [DIPHENHYDRAMINE HYDROCHLORIDE]).  The outcome of the events was not reported.
Change in smell, metallic; smell similar to spray type deodorant.; This is a spontaneous report from a contactable consumer, the patient. A 49-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8733) via an unspecified route of administration in the right arm on 04May2021 at 08:15 (at the age of 49-years-old), as a single dose for COVID-19 immunisation. Medical history included COVID-19. Prior to the vaccination, the patient was diagnosed with COVID-19. Concomitant medication was not reported. The patient did not receive any other vaccine within four weeks prior to the COVID vaccine. The patient previously received erythromycin (MANUFACTURER UNKNOWN) for unspecified indication from unknown date and experienced drug allergy. The patient previously received first dose (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EW0162) via an unspecified route of administration in the right arm on 13Apr2021 at 08:00 (at the age of 49-years-old), as a single dose for COVID-19 immunisation. On 06May2021, the patient experienced change in smell, metallic; a smell similar to spray type deodorant. Since the vaccination, the patient had not been tested for COVID-19. The events did not result in doctor or other healthcare professional office/clinic, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the event. The clinical outcome of the event change in smell, metallic was not recovered at the time of this report.  No follow-up attempts are needed. No further information is expected.
Scratching on his (R) arm swollen from elbow to shoulder (huge), in pain, very hot. CORTISONE cream was put on the arm a few times. Put cold ice compress on the arm.
Extreme swelling, redness, hot. High pain. Feeling very tired, headache, nausea, moody.
Moderna COVID-19 Vaccine EUA 1) first night after shot: significant pain at injection site and surrounding area. symptoms lasted 1.5 days. 2) 4 days after shot: fever of 100.3F, chills, severe headache, weakness, tiredness. took 3 doses of tylenol and aleve. symptoms lasted 24hrs.
Patient described feeling of tenderness and inflammation   on right arm below elbow when touched, area would move location and size would shrink and expand between 4 - 8 inches, no visible abnormalities, stated felt was on surface of skin, lasted from Friday evening to Saturday noon.
Pt vaccinated with DTP/OPV no adverse effects according to father; Pt was fine the day after immunization. Pt discovered not breathing at 2AM 31OCT.
Administered vaccine that was stored at temperature between -80 degree F to -84 degree F; Administered vaccine that was stored at temperature between -80 degree F to -84 degree F; This spontaneous case was reported by a nurse and describes the occurrence of PRODUCT STORAGE ERROR (Administered vaccine that was stored at temperature between -80 degree F to -84 degree F) and POOR QUALITY PRODUCT ADMINISTERED (Administered vaccine that was stored at temperature between -80 degree F to -84 degree F) in an 86-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 076C21A) for COVID-19 vaccination.     No Medical History information was reported.    On 19-Nov-2021 at 3:06 PM, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) .25 milliliter. On 19-Nov-2021 at 3:06 PM, the patient experienced POOR QUALITY PRODUCT ADMINISTERED (Administered vaccine that was stored at temperature between -80 degree F to -84 degree F). On an unknown date, the patient experienced PRODUCT STORAGE ERROR (Administered vaccine that was stored at temperature between -80 degree F to -84 degree F). At the time of the report, PRODUCT STORAGE ERROR (Administered vaccine that was stored at temperature between -80 degree F to -84 degree F) and POOR QUALITY PRODUCT ADMINISTERED (Administered vaccine that was stored at temperature between -80 degree F to -84 degree F) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medication were reported.   Patients were given doses from vials that were stored in an ultracold freezer which is colder than they should have been. The vial undergone temperature excursions for 1 month. The vial was in frozen state at the time of the excursion. The vials moved from freezer to refrigerator on 19 Nov 2021. The maximum and minimum reached temperatures was negative 82 degrees Fahrenheit. The vials were returned to the freezer or refrigerator or maintained at room temperature. The reporter stated that total 70 vials were still in the ultra-cold freezer and 8 vials were in the refrigerator. No vaccine state changes were noticed. The vaccine was never refrozen. None of the vials were punctured. No previous temperature excursion issues had happened.  No treatment information was provided by the reporter.   This case was linked to MOD-2021-402935 (Patient Link).
Myalgia, Angioedema, Red, hot to touch, size of baseball at injection site Narrative:
DTaP given 8/5/02 to child's left thigh. On 8/7/02, mother noted redness to area. On 8/8/02 described by private MD as "6x7cm, unusual, firm nodular center, local inflammatory reaction". No fever.
Rash and body wide itching especially on palms of hands and feet. Gave 50mg of liquid BENADRYL and symptom became worse over next 25 minutes. Dr. from his family practitioner's office was in our store and gave a verbal for 50mg of SOLU-CORTEF IM, patient recovered fully over next 20 mins sent home w/ btl of liquid BENADRYL.
It was reported that a pt rec'd a TD adult vaccination and PPD Tubersol skin test on 4/24/01. Reportedly on 4/25/01, th pt developed a headache, body aches and feeling tired. Stated she was treated with ibuprofen, but also presented with hayfever symptoms and sore throat. From mailed follow-up correspondence rec'd on 1/13/01 it was reported that the pt recovered from this experience.
Starting 11/21/2022 in the evening, I had a sore throat and started getting congested and fatigued. I took a rapid test and it was negative. Then, the next day, I was more congested, had more sinus pressure, sinus pain, sore throat and had chills and fatigue. I got a PCR test that day. I went to the clinic on 11/23/2022 where I had a rapid test but it was negative. By Friday, 11/25/2022, I got the positive PCR result. By then, I was feeling mostly back to normal with only mild symptoms remaining. I was able to treat my symptoms with over the counter medications. As of today, I am mostly back to normal with only slight nasal congestion and slight brain fog.
Pt received the Zostavax vaccine on Saturday 1/9/10 and contacted the pharmacy the next day about her adverse event. She reported severe swelling, redness, pain and warnmth at the injection site which had worsened. The affected area was originally a 2x2 in area, but it expanded and appeared to be moving distally towards her elbow over the next 24 hours.  Pt took Benadryll and used an ice pack on Monday evening which did seem to decrease the redness, inflammation and pain. As of Thursday (1/13), the swelling and pain had dissipated significntly and the area was still itchy, but it was no longer raised or warm and pt's husband reported there was just a "pinkish tinge" to the skin.  Pt also received H1N1 vaccine at the same time in the opposite arm. Also, the Zostavax vaccine was from a brand new package with a different lot # from previous Zostavax vaccines.
Narrative: 74-year-old with a PMH of HTN, skin cancer, and DVT reported joint pain after receiving the second dose of COVID 19 Vaccine to his  outpatient clinic. Per telephone triage note, the patient went to an outside hospital's ED and received Methylprednisolone; however, he still experienced body pain. Thus, the pharmacist ordered inflammatory marker labs, CHEM-8 and INR. All labs were within normal limit. The patient was then seen by his provider and given naproxen 500 mg to help with the body pain.
Tape reaction from bandage with resultant secondary innoculation site about one inch distal from primary smallpox immunization site.
Patient states had tightness in chest, shortness of breath, headache and lightheaded. Flushing of the face, elevated blood pressure.
COVID+ 12/14/22.  Vaccination status - pfizer x3 + Pfizer BIVALENT BRIEF OVERVIEW: Admission Date: 12/14/2022 Discharge Date:  12/15/2022   Active Hospital Problems   Diagnosis Date Noted POA ? Paroxysmal atrial fibrillation 10/01/2015 Yes ? Diabetes mellitus type 2 with complications 10/01/2015 Yes ? Acute kidney injury superimposed on chronic kidney disease 09/28/2022 Yes ? Lab test positive for detection of COVID-19 virus 12/14/2022 Yes ? Failure to thrive in adult 12/14/2022 Yes ? Chronic obstructive pulmonary disease 11/22/2022 Yes ? Diastolic heart failure   Yes ? Iron deficiency anemia   DETAILS OF HOSPITAL STAY: PRESENTING PROBLEM: Failure to thrive in adult   HOSPITAL COURSE: 78 yo female with COPD on 4 liters 02 recently hospitalized with CHF, Afib with RVR, and discharged to care facility. Returned to ED last eveniong after testing Covid = in the facility, and having symptoms of head congestion and shortness of breath. Labs showed worse renal function compared to baseline (Creat 1.8 c/t 1.5) and findings of mild CHF on CXR. She received 10 mg Dexamethasone IV in ED last night and 10 mg of po torsemide additional. Today she says she feels much better. She is breathing comfortably on her usual 4 liters 02 per NC and her lungs sound clear on exam. She is anxious to discharge home and with be discharged there with home health care. The only me change is a medrol dose pack over 6 days, beginng tomorrow afeter receiving 32 mg of Medrol po in the hospital today before discharge.
SOB, BP 161/105 (pulse 96). F/u BP 144/96 (pulse 79).
On 8/14/13 patient received the DTAP and IPV vaccine and developed redness/itching in the left arm 18 hrs following administration of vaccines.
Patient said he did not have a Covid vaccine before, but when we were logging the dose into our state's IIS it showed he did get a dose of Pfizer on 6/19/21.
Patient was given injection that expired on 06/25/21.  Injection given 06/30/21 The patient has not called with any problems. Moderna has been notified and we are still waiting for the company to tell us what we need to do.
headache; night sweats; achy; chills; last menstrual date 19Dec2020 and first administration date=29Dec2020; This is a spontaneous report from a contactable nurse reporting for herself.   A 31-year-old pregnant female patient received her first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 MRNA VACCINE), lot number: EH9899, via an unspecified route of administration on 29Dec2020 at 13:00 (at the age of 31 years old) as a single dose in the left arm for COVID-19 immunisation. Medical history included seasonal allergies from an unknown date, acid reflux disease from an unknown date, headaches from an unknown date, and irritable bowel syndrome from an unknown date.  Concomitant medication included pantoprazole sodium sesquihydrate (PROTONIX), prenatal vitamins, cetirizine hydrochloride (ZYRTEC), and unspecified allergy shot. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient experienced headache on an unspecified date, night sweats on an unspecified date, achy on an unspecified date, chills on an unspecified date, and last menstrual date 19Dec2020 and first administration date of 29Dec2020. The mother was due to deliver on 25Sep2021. The patient did not receive treatment for the events. The outcome of the events headache, night sweats, achy and chills, and exposure during pregnancy was unknown. It was also reported that since the vaccination, the patient had not been tested for COVID-19.
Patient has not reported any adverse events; the vaccine was administered after the beyond use date of 3/3/2023
Information has been received from a physician assistant concerning a female patient who in "2007" was vaccinated with the first dose of GARDASIL.  Then the patient received the other two doses of GARDASIL and later on when she had PAP (Papanicolaou) smear test the result showed that the HPV positive was at high risk.  The patient sought unspecified medical attention.  At the time of the report, the patient's outcome was unknown.  This is one of several reports from the same source.  Additional information has been requested.
Acute coronavirus disease-19 viral pneumonia with acute hypoxemic respiratory failure + COVID 19 test
Today was the third and final shot of the rabies series vaccination. During each of the three shots, I experienced tingling and itchiness of cheek muscles proceeding to the lips approximately 15 minutes after shot administration. The second shot's reaction (10/29/2012) was the worst of the series with the side effects lasting four hours.  During the first (10/22/2012) and third shots, the effects lasted about 15 and 60 minutes respectively.
Sore arm; Headache; Feeling off; Sometimes lightheaded; Racing heartbeat; Tired; leg that had DVT sometimes getting sharp pain for a few seconds; This is a spontaneous report from a contactable consumer, the patient. A 59-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 25Apr2021 at 14:30 (at the age of 59-years-old) as a single dose for COVID-19 immunisation. Medical history included hypothyroidism, blood pressure high and DVT (deep vein thrombosis) of legs. The patient had unspecified allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient received other medications within 2 weeks of vaccination. On 26Apr2021 at 06:30, the patient experienced sore arm for 3 days so far, headache, feeling off, sometimes lightheaded, she had prior DVT and leg that had DVT sometimes getting sharp pain for a few seconds racing heartbeat, tired. The events had not resulted in doctor/other health care professional office/clinic visit and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event sore arm, headache, feeling off, sometimes lightheaded, she had prior DVT and leg that had DVT sometimes getting sharp pain for a few seconds racing heartbeat, tired were not resolved at the time of this report.  No follow-up attempts are required; information about lot/batch number cannot be obtained. No further information is expected.
Vaccine that administered beyond use date after the thaw process; This spontaneous case was reported by a paramedic and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Vaccine that administered beyond use date after the thaw process) in a 55-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 030h21b) for COVID-19 prophylaxis.     No Medical History information was reported.    On an unknown date, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) .25 milliliter. On an unknown date, the patient experienced EXPIRED PRODUCT ADMINISTERED (Vaccine that administered beyond use date after the thaw process). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Vaccine that administered beyond use date after the thaw process) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Patient age was reported as 55 years 2 months. Concomitant products were not provided.  It was unknown if patient had acute illness at the time of vaccination and up to one month before. It was unknown if patient had been diagnosed with or tested positive for COVID-19, nor if patient had chronic or long lasting health conditions. It was reported that patient had no adverse reactions after the administration of vaccine.  The vaccination facility was made aware of administration of vaccines beyond use date after the thaw process while audit was conducted. Patient got Moderna with vaccine Ndc code 80777-0273-99.   Treatment medications were not reported.
I am patient's primary care provider. He reported to me yesterday, 4/21/21, that he received his first dose of Pfizer on 4/9, and subsequently developed a fever and seized later that day.
pt recv vax & w/in 15 mins felt faint & developed hypotension, followed by urticaria; 16NOV94 exp pruritus, also devel rash; devel dry & scaly skin, low grade fever of 100 to 101 & exp a feeling that face was hot; flu-like sx;
Employee, received 2 immunizations on 6-23-2011. On 6-24-11 employee woke up with 100.0 F fever, sore throat, and body aches.
w/in 3 days of vax pt devel lt upper jaw pain & w/in 5 days became SOB (pt thought might be having MI);also devel abd distention,constipation/diarrhea;ER r/o sinusitis,hepatitis,bowel obstruction;echocardiogram done 2JAN96;fever
Side effects; Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by a consumer and describes the occurrence of ADVERSE REACTION (Side effects) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced ADVERSE REACTION (Side effects). At the time of the report, ADVERSE REACTION (Side effects) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant medications were reported. No treatment medications were reported.   Reporter did not allow further contact
Pt came back with c/o a painful deltoid muscle where she received the flu vaccine 1 month ago. Ice/warm packs to arm alternating. Return for recheck.
Information has been received from a physician concerning an approximately 70 year old male who was vaccinated with ZOSTAVAX (Oka/Merck) SC (no lot no. provided). Subsequently the patient experienced small rash a couple of weeks after ZOSTAVAX vaccination. The physician reported that as of 06-AUG-2008, the rash was crusting over and it looks that the patient was improving. The patient sought unspecified medical attention. Additional information has been requested.
possibly infected right breast; inflamed; Swollen; nipple (lymph node); nipple (lymph node); This is a spontaneous report from a contactable consumer (Patient). A 34-years-old male patient received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, formulation: Solution for injection, Lot Number: EN6207), dose 1st via an unspecified route of administration, administered in Left arm on 23Mar2021 13:15 as single dose for covid-19 immunization. The patient medical history and concomitant medications were not reported. The patient experienced possibly infected right breast, inflamed, swollen, nipple (lymph node) all were on 26Mar2021 12:00. No other vaccine in four weeks. No COVID prior vaccination. No treatment was given for events. The patient has not tested COVID-19 Since the vaccination. The outcome of the events was recovering.
pt recv vax;low grade fever w/ questionable sz lasting sec;questionable post-ictal phase of dec level of activity w/ :glazed" look to eyes;in er where afebrile,nl physical exam;er MD did not think it was a sz; "nl" at discharge;
had reactions to things I'm not allergic to; Vomit; issues with breathing; high fever; Chills; This is a spontaneous report from a contactable consumer (patient). A male patient of an unspecified age received BNT162B2 (PFIZER-BIONTECH COVID-19 MRNA VACCINE), via an unspecified route of administration, administered in Arm Left on 29Apr2021 10:00 (Batch/Lot Number: Ep7534) as 2nd dose, single for COVID-19 immunization. Medical history included egg allergy and anaphylactic reactions from an unknown date and unknown if ongoing. The patient previously took dose 1 of BNT162B2 in the left arm lot number: Er8732 on 09Apr2021 10:00 AM for COVID-19 immunization. Concomitant medications included amoxicillin taken for an unspecified indication, start and stop date were not reported. The facility where the most recent COVID-19 vaccine was administered was in the doctor's office/urgent care. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient has not been tested for COVID-19. On 30Apr2021, at 2AM, the patient had high fever and chills lasted most of night. The patient stated that on 30Apr2021 12:00, "I have an egg allergy and occasionally have anaphylactic reactions when I have it. Strangely anytime I ate or drank anything for the day after my shot I had reactions to things I'm not allergic to. This manifested itself in needing to vomit then later it triggered issues with breathing and was quite concerning." The events resulted in doctor or healthcare professional office/clinic visit. The patient was treated with Prednisone. The outcome of the event was recovered on unspecified date. The events were serious per hospitalization on 30Apr2021 reported from health authority.  Information on Lot/Batch number was available. Additional information has been requested.